Satsuma Pharmaceuticals, Inc. (STSA)


0.00 (0.00%)
Symbol STSA
Price $1.1
Beta 0.102
Volume Avg. 1.11M
Market Cap 36.468M
Shares () -
52 Week Range 0.59-8.08
1y Target Est -
DCF Unlevered STSA DCF ->
DCF Levered STSA LDCF ->
ROE 754.54% Strong Buy
ROA -145.67% Strong Sell
Operating Margin -
Debt / Equity 0.31% Neutral
P/E -0.55
P/B 0.97 Buy


Consensus EPS

Upgrades & Downgrades

Latest STSA news

Mr. John A. Kollins MBA
NASDAQ Global Market

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.